OGEN - Oragenics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
1.52
-0.16 (-9.52%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.68
Open1.66
Bid0.00 x 1000
Ask0.00 x 3000
Day's Range1.49 - 1.66
52 Week Range0.60 - 6.80
Volume123,862
Avg. Volume730,769
Market Cap9.252M
Beta1.51
PE Ratio (TTM)N/A
EPS (TTM)-1.39
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Diamond Equity Research Initiates Coverage on Oragenics Inc. (NYSE:OGEN) with a Valuation of $3.50 Per Share

    NEW YORK, June 20, 2018 (GLOBE NEWSWIRE) -- via NetworkWire - Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Oragenics Inc. (OGEN). The in-depth 29-page initiation report includes detailed information on the Oragenics's business model, services, industry, valuation, management, and risks. The full research report is available here.

  • Business Wire11 days ago

    Oragenics, Inc. Announces Peer-Reviewed Publication Detailing Discovery of OG716 for C. difficile infections

    Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a clinical stage biotechnology company, today announced the publication of a research paper entitled “OG716: designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections” in PLOS ONE, a peer-reviewed open access scientific journal published by the Public Library of Science. Researchers sought to discover a lead candidate for the treatment of Clostridium difficile (C. difficile) based on a second-generation library of over 300 variants of the lantibiotic Mutacin 1140 (MU1140). MU1140 remains an attractive lantibiotic due to its novel mechanism of action that may limit the development of drug resistance.

  • Zacks Small Cap Research13 days ago

    OGEN: Initiating Coverage of Oragenics, Inc.; Developing a Novel Class of Antibiotics and Treatment for Oral Mucositis

    We are initiating coverage of Oragenics, Inc. (OGEN) with a $7.00 valuation. Oragenics is a biopharmaceutical company developing a new treatment for oral mucositis (OM) and a novel class of antibiotics. AG013 is the company’s lead product for the treatment of OM, a painful inflammation and ulceration of the lining of the mouth, throat, and esophagus that is one of the most common side effects of cancer chemotherapy and radiation treatment.

  • Is Oragenics Inc’s (NYSEMKT:OGEN) CEO Paid At A Competitive Rate?
    Simply Wall St.19 days ago

    Is Oragenics Inc’s (NYSEMKT:OGEN) CEO Paid At A Competitive Rate?

    Alan Joslyn took the reins as CEO of Oragenics Inc’s (AMEX:OGEN) and grew market cap to US$8.52M recently. Understanding how CEOs are incentivised to run and grow their company isRead More...

  • ACCESSWIRE24 days ago

    Today’s Research Reports on Stocks to Watch: Oragenics and Sigma Labs

    NEW YORK, NY / ACCESSWIRE / May 31, 2018 / Oragenics and Sigma Labs were both big winners in the biotech arena on Wednesday. Shares of Oragenics climbed higher after announcing positive results from its interim safety analysis on patients from its Phase 2 clinical trial of AG013. AG013 is a promising product for the prevention of oral mucositis in cancer patients.

  • Business Wire25 days ago

    Oragenics Reports Positive Interim Safety Analysis Results from Its Phase 2 Clinical Trial of AG013 for Oral Mucositis

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced positive results from its interim safety analysis as requested by FDA on patients from its Phase 2 clinical trial of AG013 for the treatment of OM. The study provides information that, we believe, likely indicates that the overall incidence of severe OM is less than would be anticipated in the general population. Safety was evaluated on the basis of treatment-emergent adverse events, vital signs, weight, physical examinations, clinical laboratory assessments and the presence of AG013 in whole blood.

  • ACCESSWIRE26 days ago

    Nektar Therapeutics and Three Additional Biotech Stocks on Our Research Desk’s Radar

    Stock Research Monitor: MBRX, OGEN, and OTIC LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want a free Stock Review on NKTR sign up now at www.wallstequities.com/registration . On Friday, May 25, 2018, ...

  • Business Wirelast month

    Oragenics, Inc. and Texas A&M University System Granted U.S. Patent for Lantibiotic MU1140

    Among other things, the patent covers the unique variants of the lantibiotic 1140 (MU1140) and other lantibiotics with improved pharmacological properties and structural features as well as the methods of using these compositions to treat and prevent infections, diseases, and colonization by one or more types of bacteria. “In recent years, antibiotic resistant bacteria have been on the rise, affecting millions of people worldwide and resulting in an increasingly large burden on the healthcare system. Lantibiotics serve as an important class of antibiotics with the potential to serve in the treatment of problematic infections caused by Gram-positive bacteria, while also potentially limiting the development of drug resistance,” Alan Joslyn, chief executive officer and president of Oragenics, said.

  • Who Are The Top Investors In Oragenics Inc (NYSEMKT:OGEN)?
    Simply Wall St.2 months ago

    Who Are The Top Investors In Oragenics Inc (NYSEMKT:OGEN)?

    In this analysis, my focus will be on developing a perspective on Oragenics Inc’s (AMEX:OGEN) latest ownership structure, a less discussed, but important factor. Ownership structure has been found toRead More...

  • Does Oragenics Inc (NYSEMKT:OGEN) Fall With The Market?
    Simply Wall St.2 months ago

    Does Oragenics Inc (NYSEMKT:OGEN) Fall With The Market?

    For Oragenics Inc’s (AMEX:OGEN) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. OGEN is exposed toRead More...

  • Business Wire3 months ago

    Oragenics, Inc. Announces Pricing of $1.8 Million Registered Direct Offering

    Florida-based biopharmaceutical company Oragenics, Inc.  today announced that it has entered into a securities purchase agreement with certain new institutional investors providing for the purchase and sale of 900,000 shares of common stock at a price of $2.00 per share in a registered direct offering, resulting in total gross proceeds of approximately $1.8 million.

  • Business Wire3 months ago

    Oragenics Completes Enrollment for the Interim Analysis Cohort in Its Phase 2 Clinical Trial of AG013 for Oral Mucositis

    Oragenics, Inc. , a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that it has completed enrollment of the interim analysis cohort of 20 patients in its Phase 2 clinical trial of AG013 for the treatment of oral mucositis .

  • Business Wire3 months ago

    Oragenics, Inc. Announces Peer Reviewed Publication Examining Efficacy of Mutacin 1140 Lantibiotic Variants against Clostridium difficile

    Oragenics, Inc. , a clinical stage biotechnology company, today announced the publication of a research paper entitled “Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection” in the peer reviewed journal, Frontiers in Microbiology, the largest microbiology journal in the world.

  • Did Oragenics Inc’s (NYSEMKT:OGEN) Earnings Growth Outperform The Industry?
    Simply Wall St.3 months ago

    Did Oragenics Inc’s (NYSEMKT:OGEN) Earnings Growth Outperform The Industry?

    After looking at Oragenics Inc’s (AMEX:OGEN) latest earnings announcement (31 December 2017), I found it useful to revisit the company’s performance in the past couple of years and assess thisRead More...

  • ACCESSWIRE4 months ago

    Oragenics, Inc. to Present at The MicroCap Conference on April 9th and 10th in New York City at the Essex House

    NEW YORK, NY / ACCESSWIRE / March 6, 2018 / Oragenics, Inc. (NYSE American: OGEN) will be presenting at this year's MicroCap Conference on April 9 th and 10 th in New York City. CONFERENCE OVERVIEW AND ...

  • Business Wire4 months ago

    Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

    Oragenics, Inc. today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2017, which was filed on February 16, 2018 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included a going concern emphasis of matter paragraph....

  • Business Wire5 months ago

    Oragenics, Inc. Announces Reverse Stock Split

    Florida-based biopharmaceutical company Oragenics, Inc.  today announced a reverse split of its common stock, $0.001 par value, at a ratio of 1 for 10, effective January 19, 2018 .

  • Oragenics Inc (OGEN) Earnings: Did It Outperform The Industry?
    Simply Wall St.7 months ago

    Oragenics Inc (OGEN) Earnings: Did It Outperform The Industry?

    Assessing Oragenics Inc’s (AMEX:OGEN) past track record of performance is a valuable exercise for investors. It enables us to reflect on whether the company has met or exceed expectations, whichRead More...

  • Business Wire7 months ago

    Oragenics, Inc. Regains Compliance with NYSE American Continued Listing Standards

    Florida-based biopharmaceutical company Oragenics, Inc.  today announced receipt of notification from the NYSE American LLC that the Company has regained compliance with the Exchange’s listing requirements.

  • Business Wire7 months ago

    Oragenics Announces Closing of $3.3 Million Preferred Stock Private Placement and $3.4 Million Debt Conversion into Equity

    Oragenics, Inc. , a clinical stage biotechnology company, today announced that it has completed a private placement of $3.3 million of Non-Voting Series B Convertible Preferred Stock with four existing shareholders who are accredited investors including an entity affiliated with a director of the Company .

  • Oragenics Inc (OGEN): Time For A Financial Health Check
    Simply Wall St.8 months ago

    Oragenics Inc (OGEN): Time For A Financial Health Check

    Oragenics Inc (AMEX:OGEN) is a small-cap stock with a market capitalization of USD $17.25M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...

  • Is Oragenics Inc (OGEN) A Good Healthcare Bet?
    Simply Wall St.9 months ago

    Is Oragenics Inc (OGEN) A Good Healthcare Bet?

    Oragenics Inc (AMEX:OGEN), a USD$23.65M small-cap, operates in the healthcare industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population, impactingRead More...

  • Business Wire10 months ago

    Oragenics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

    Oragenics, Inc. , a leader in the development of novel antibiotics against infectious diseases and innovative treatments for oral mucositis, today announced that it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, being held on September 10-12, 2017 at The Lotte New York Palace Hotel in New York City.

  • Business Wire10 months ago

    Oragenics Doses First Patient in Phase 2 Clinical Trial of AG013 for Oral Mucositis

    Oragenics, Inc. , a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that the first patient has been dosed in its Phase 2 clinical trial of AG013 for the treatment of oral mucositis .

  • Associated Press10 months ago

    Oragenics reports 2Q loss

    On a per-share basis, the Tampa, Florida-based company said it had a loss of 2 cents. In the final minutes of trading on Monday, the company's shares hit 36 cents. A year ago, they were trading at 71 cents. ...